|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 15:48
|
Is Hims & Hers Really the Growth Stock to Buy That It Appears? (24/7 Wall St.)
|
|
|
Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA's aggressive crackdown on compounded GLP-1 drugs, complete with warning letters accusing misleading marketing. Threats of Justice Dept. criminal investigations loomed, and Novo Nordisk (NYSE:NVO) slapped the company with a patent-infringement lawsuit over knockoff ... Is Hims & Hers Really the Growth Stock to Buy That It Appears?
The post Is Hims & Hers Really the Growth Stock to Buy That It Appears? appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
11.03.26 - 15:12
|
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook (24/7 Wall St.)
|
|
|
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen Santangelo raised his price target on Hims & Hers Health to $29 from $25, keeping an Overweight rating, after the company's deal with ... Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
The post Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook appeared first on 24/7 Wall St.....
|
|
|
|
|
11.03.26 - 01:09
|
Hims & Hers Names Kathryn Beiser as Chief Communications Officer (Business Wire)
|
|
|
The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growthSAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the future.
A seasoned communications leader, Beiser has expertise launching, building, and elevating corporate brands in highly regulated industries, serving as the Chief Communications Officer for companies including Discover, Kaiser Permanente, and, most recently, Eli Lilly and Company, a...
|
|
|
|
|
11.03.26 - 01:01
|
Hims & Hers Aktie springt 40% nach möglicher Partnerschaft mit Novo Nordisk (Ariva)
|
|
|
Novo Nordisk und Hims & Hers wollen ihren Streit um Abnehmmedikamente offenbar beilegen und könnten mit einer neuen GLP-1-Partnerschaft den Markt aufmischen. Der dänische Pharmakonzern Novo Nordisk und der US-Telemedizinanbieter Hims & Hers könnten laut Blomberg vor einer Partnerschaft im Markt für Abnehmmedikamente stehen. Damit könnte ein monatelanger Konflikt über den Verkauf von GLP-1-Präparaten beigelegt werden, der ......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
